Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1. Originally developed for type 2 diabetes management, it has gained significant attention for its effects on body weight regulation. The peptide consists of a modified GLP-1 sequence with amino acid substitutions and a fatty acid chain that enables albumin binding, dramatically extending its half-life compared to native GLP-1.

Semaglutide activates GLP-1 receptors in multiple tissues. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. In the brain, particularly the hypothalamus and brainstem, it activates anorexigenic pathways that reduce appetite and food intake. The peptide also slows gastric emptying, contributing to prolonged satiety.

Following subcutaneous administration, semaglutide reaches peak plasma concentration in 1-3 days. The albumin-binding fatty acid modification results in a terminal half-life of approximately 7 days, enabling once-weekly dosing.

Note: These are research protocols from literature. This is not medical advice.

Peptides that may be combined based on complementary mechanisms in research settings.

• 1STEP trials demonstrated mean weight loss of 14.9% with 2.4mg weekly dosing over 68 weeks
• 2SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiovascular events
• 3Significant improvements in glycemic control with HbA1c reductions of 1.5-2.0%
• 4Demonstrated hepatoprotective effects with reductions in liver fat content

Refrigerate at 2-8C. After first use, may store at room temperature for 56 days.

Scientific References

• 1
  Once-Weekly Semaglutide in Adults with Overweight or Obesity

  Wilding JPH, et al.

  NEJM, 2021 | DOI: 10.1056/NEJMoa2032183

• 2
  Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

  Lincoff AM, et al.

  NEJM, 2023 | DOI: 10.1056/NEJMoa2307563